Ginkgo Bioworks Holdings, Inc.
DNA
$7.71
-$0.14-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 141.31M | 160.07M | 170.52M | 220.73M | 227.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 141.31M | 160.07M | 170.52M | 220.73M | 227.33M |
| Cost of Revenue | 38.02M | 39.02M | 41.34M | 40.54M | 39.44M |
| Gross Profit | 103.29M | 121.05M | 129.18M | 180.19M | 187.89M |
| SG&A Expenses | 172.08M | 176.19M | 182.16M | 189.50M | 212.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 432.87M | 458.98M | 493.52M | 507.71M | 610.47M |
| Operating Income | -291.56M | -298.91M | -323.00M | -286.99M | -383.14M |
| Income Before Tax | -298.87M | -305.95M | -332.42M | -308.44M | -464.85M |
| Income Tax Expenses | -1.01M | -837.00K | -519.00K | -895.00K | -422.00K |
| Earnings from Continuing Operations | -297.87 | -305.12 | -331.90 | -307.55 | -464.43 |
| Earnings from Discontinued Operations | -6.53M | -7.65M | -7.65M | -7.65M | -7.65M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -304.39M | -312.76M | -339.55M | -315.19M | -472.08M |
| EBIT | -291.56M | -298.91M | -323.00M | -286.99M | -383.14M |
| EBITDA | -253.34M | -258.67M | -280.77M | -241.05M | -336.97M |
| EPS Basic | -5.35 | -5.64 | -6.23 | -5.85 | -8.98 |
| Normalized Basic EPS | -2.97 | -3.08 | -3.40 | -2.95 | -4.07 |
| EPS Diluted | -5.36 | -5.65 | -6.23 | -5.86 | -8.99 |
| Normalized Diluted EPS | -2.97 | -3.08 | -3.40 | -2.95 | -4.07 |
| Average Basic Shares Outstanding | 227.14M | 221.82M | 218.55M | 215.16M | 211.67M |
| Average Diluted Shares Outstanding | 227.14M | 221.82M | 218.55M | 215.16M | 211.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |